retatrutide 8 weeks Retatrutide, an experimental weight-loss drug, has not been approved by the FDA Week 8 Check-In: First Refeed

Since Retatrutide targets glucagon receptors, increasing insulin sensitivity and reducing blood sugar, it could be an effective treatment for people with type 2 diabetes (1)

However, prescription Egrifta requires a valid prescription

In its formal guidance, the FDA disclosed that it has issued warning letters to illicit entities distributing active pharmaceutical ingredients, explicitly naming retatrutide

FDA Newsroom

For patients who have spent years cycling through diets and blaming themselves, these medications offer something rare: a pause

For example, in the DiRECT study of people with obesity and diabetes, very severe caloric restriction leading to a loss of 15% of body weight led to complete remission of type 2 diabetes in 85% of participants